10-Q: Cannabis Bioscience International Holdings Reports Q2 2024 Results Amidst Operational Shifts

Cannabis Bioscience International Holdings reports a net loss of $306,217 for the six months ended November 30, 2023, amidst ongoing operational adjustments and the impact of the COVID-19 pandemic.

Summary

• Cannabis Bioscience International Holdings reported a net loss of $306,217 for the six months ended November 30, 2023, compared to a net loss of $431,917 for the same period in 2022.
• Revenue decreased to $136,569 for the six months ended November 30, 2023, from $219,162 in the prior year, primarily due to a decline in clinical trial revenue.
• Operating expenses decreased to $380,839 from $589,443 year-over-year, mainly due to a reduction in contract labor costs.
• The company's cash position is weak, with only $337 in cash and cash equivalents as of November 30, 2023.
• The company has a negative working capital of $640,567 as of November 30, 2023.
• The company's accumulated deficit is $4,988,956 as of November 30, 2023.
• The company issued 272,071,428 shares of common stock for $56,000 during the six months ended November 30, 2023, net of a rescission of 19,000,000 shares for $19,000.
• The company's ability to continue as a going concern is dependent on raising additional capital and executing its operating plan.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including declining revenue, low cash reserves, and a negative working capital. While there are some improvements in operating expenses, the overall outlook is concerning, suggesting a negative sentiment.

Positives

• The company's net loss decreased year-over-year, indicating some improvement in financial performance.
• Operating expenses decreased significantly, primarily due to a reduction in contract labor costs.
• The company is resuming normal operations in its Pharmacology University and Alpha Research businesses after the lifting of COVID-19 restrictions.

Negatives

• The company experienced a significant decrease in revenue, particularly in clinical trials.
• The company has a very low cash balance of $337.
• The company has a substantial negative working capital of $640,567.
• The company has a large accumulated deficit of $4,988,956.
• The company's ability to continue as a going concern is uncertain.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and executing its operating plan.
• The company's low cash balance and negative working capital pose significant financial risks.
• The company's revenue is highly dependent on a few customers, creating a concentration risk.
• The company's operations were negatively impacted by the COVID-19 pandemic, and future outbreaks could further disrupt business.
• The company's net operating loss carryforwards are subject to annual limitations due to changes in ownership provisions.

Future Outlook

The company's ability to continue as a going concern depends on the successful execution of its operating plan, which includes expanding its operations and raising either debt or equity financing. There is no assurance that the Company will be able to expand its operations or obtain such financing on satisfactory terms or at all.

Management Comments

• The Company believes that it may have been negatively impacted by the association of the pandemic with the Peoples Republic of China because China appeared in its former corporate name.
• The Company is resuming normal operations in its Pharmacology University and Alpha Research Businesses.

Industry Context

The company operates in the medical cannabis and clinical trials sectors, which are experiencing growth but also face regulatory and market challenges. The company's educational programs and clinical trial services are part of a broader trend towards increased research and acceptance of cannabis-based therapies.

Comparison to Industry Standards

• The company's revenue decline in clinical trials contrasts with the general growth trend in the clinical research industry, where many companies are experiencing increased demand.
• The company's negative working capital and low cash position are significantly below industry benchmarks for companies in the biotechnology and healthcare sectors.
• Compared to companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) or Canopy Growth, which have established revenue streams and significant funding, Cannabis Bioscience International Holdings is in a much more precarious financial position.
• The company's reliance on a few key customers is a significant risk, unlike larger, more diversified companies in the sector.

Management Changes

Related Party Transactions

• The company leases office space from two of its officers on a month-to-month basis.
• The balance of related party liabilities owed to certain shareholders totaled $224,717 and $105,173 at November 30, 2023, and May 31, 2023, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and uncertainty about its ability to continue as a going concern.
• Employees may be impacted by potential cost-cutting measures or operational changes.
• Customers may experience disruptions in services if the company's financial situation does not improve.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to successfully execute its operating plan, which includes expanding its operations and raising either debt or equity financing.
• The company needs to resume normal operations in its Pharmacology University and Alpha Research Businesses.
• The company needs to address its negative working capital and low cash position.

Key Dates

Keywords

Cannabis Bioscience, Clinical Trials, Medical Cannabis, Education, Financial Results, Going Concern, COVID-19, Revenue, Operating Expenses, Net Loss